Actinium Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $4.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Actinium Pharmaceuticals’ promising developments in prostate cancer treatment. The company’s latest asset, ATNM-400, has shown significant advancements in preclinical studies, particularly in its ability to target tumors specifically and maintain prolonged control over tumor growth. These findings were presented at the 4th Annual Targeted Radiopharmaceuticals Summit, highlighting the potential of ATNM-400 as a radiopharmaceutical therapy based on actinium-225.
Moreover, the preclinical data demonstrated that ATNM-400 exhibits sustained efficacy in models resistant to enzalutamide, a common prostate cancer treatment, both as a standalone therapy and in combination with enzalutamide. This efficacy surpasses that of existing treatments like Pluvicto, offering hope for patients with limited options after progressing beyond PSMA-targeted therapies. The unique targeting mechanism of ATNM-400, which focuses on an alternative target overexpressed in prostate cancer, further supports Pantginis’s positive outlook on Actinium Pharmaceuticals’ potential in addressing unmet medical needs in this field.
Pantginis covers the Healthcare sector, focusing on stocks such as Krystal Biotech, Capricor Therapeutics, and Cytokinetics. According to TipRanks, Pantginis has an average return of -16.7% and a 33.07% success rate on recommended stocks.